Sensorium reports positive Phase 1a data for SNTX-2643
The drug showed rapid CNS activity and safety in healthy volunteers. Data were presented at Psych Congress 2026.
See the latest news and media coverage for Sensorium. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biotechnology company developing nature-derived CNS therapies
sensorium.bioLast updated
In short: Sensorium advanced its clinical pipeline, securing FDA IND clearance for SNTX-2643, raising $25M, and presenting Phase 1a anxiety trial data.
The drug showed rapid CNS activity and safety in healthy volunteers. Data were presented at Psych Congress 2026.
He reported feeling energized by advances in new agents, DSM evolution, and AI integration.
The report shows 1.17 billion people have a mental health disorder, making it the leading cause of disability.
The first-in-class anxiolytic is a precision serotonin modulator, with first-in-human dosing in Q3 2025.
Sensorium Therapeutics, a clinical-stage central nervous system (CNS) biotechnology company developing mechanistically novel small-molecule medicines for psychiatric and neurological disorders, today announced positive results from...
Company also announces appointment of Cole Brown, M.D., as Chief Medical Officer and formation of a Clinical Advisory Board CAMBRIDGE, Mass., May 27, 2026 /PRNewswire...
Sensorium Therapeutics, a Boston, MA-based neuroscience therapeutics company, raised $25m in Series A funding...
BOSTON, July 8, 2025 /PRNewswire/ -- Sensorium Therapeutics, Inc. (Sensorium), a neuroscience therapeutics company inspired by nature and guided by human biology to transform mental...
Track Sensorium and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Sensorium and other trending companies.